Clinical Trials Browser

Phase 2/3 × Bortezomib × Other hematologic neoplasm × Clear all

NCT03117751 2025-12-05

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Phase 2/3 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma